Wall Street analysts expect that Aldeyra Therapeutics, Inc (NASDAQ:ALDX) will post earnings of ($0.43) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Aldeyra Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.44) and the highest estimate coming in at ($0.42). Aldeyra Therapeutics reported earnings per share of ($0.37) during the same quarter last year, which would indicate a negative year-over-year growth rate of 16.2%. The business is expected to issue its next quarterly earnings results on Thursday, April 4th.
According to Zacks, analysts expect that Aldeyra Therapeutics will report full year earnings of ($1.83) per share for the current fiscal year, with EPS estimates ranging from ($1.85) to ($1.80). For the next fiscal year, analysts anticipate that the business will report earnings of ($1.73) per share, with EPS estimates ranging from ($1.75) to ($1.71). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research firms that cover Aldeyra Therapeutics.
Aldeyra Therapeutics (NASDAQ:ALDX) last issued its quarterly earnings results on Wednesday, November 14th. The biotechnology company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.05).
A number of research analysts recently issued reports on the stock. Zacks Investment Research upgraded shares of Aldeyra Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, December 12th. BidaskClub upgraded shares of Aldeyra Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday. ValuEngine downgraded shares of Aldeyra Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, September 14th. Cantor Fitzgerald reiterated a “buy” rating and issued a $30.00 price target on shares of Aldeyra Therapeutics in a research note on Wednesday, November 14th. Finally, Janney Montgomery Scott lifted their price target on shares of Aldeyra Therapeutics to $28.00 and gave the stock a “positive” rating in a research note on Thursday, September 27th. Four investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Aldeyra Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $27.50.
Shares of Aldeyra Therapeutics stock opened at $9.51 on Tuesday. Aldeyra Therapeutics has a 52-week low of $6.25 and a 52-week high of $16.70. The company has a quick ratio of 4.82, a current ratio of 4.82 and a debt-to-equity ratio of 0.03. The company has a market capitalization of $254.83 million, a P/E ratio of -6.79 and a beta of 0.86.
Large investors have recently modified their holdings of the company. Rhumbline Advisers purchased a new stake in shares of Aldeyra Therapeutics during the 2nd quarter worth approximately $113,000. Hillsdale Investment Management Inc. purchased a new stake in shares of Aldeyra Therapeutics during the 3rd quarter worth approximately $131,000. National Asset Management Inc. purchased a new stake in shares of Aldeyra Therapeutics during the 3rd quarter worth approximately $193,000. Marshall Wace LLP purchased a new stake in shares of Aldeyra Therapeutics during the 3rd quarter worth approximately $219,000. Finally, Schwab Charles Investment Management Inc. purchased a new stake in shares of Aldeyra Therapeutics during the 2nd quarter worth approximately $237,000. Institutional investors and hedge funds own 68.38% of the company’s stock.
About Aldeyra Therapeutics
Aldeyra Therapeutics, Inc, a biotechnology company, focuses on the development of products for inflammation, inborn errors of metabolism, and other diseases in the United States and internationally. It is developing ADX-102, a small molecule designed to trap and allow for the degradation of aldehydes, as well as ADX-103 and ADX-104 novel candidates for the treatment of noninfectious anterior uveitis, allergic conjunctivitis, dry eye syndrome, sjögren-larsson syndrome, and succinic semi-aldehyde dehydrogenase deficiency.
Featured Story: What is a capital gain?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aldeyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.